View Financial HealthOncoTherapy Science 배당 및 자사주 매입배당 기준 점검 0/6OncoTherapy Science 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-28.4%자사주 매입 수익률총 주주 수익률-28.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. 2 independent directors (3 non-independent directors). Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.공고 • Nov 07OncoTherapy Science, Inc. to Report Q2, 2026 Results on Nov 07, 2025OncoTherapy Science, Inc. announced that they will report Q2, 2026 results on Nov 07, 2025공고 • Aug 08OncoTherapy Science, Inc. to Report Q1, 2026 Results on Aug 08, 2025OncoTherapy Science, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025공고 • May 09+ 1 more updateOncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025OncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025.공고 • Apr 28OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management LimitedOn April 28, 2025, OncoTherapy Science, Inc., closed the transaction.공고 • Apr 10OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding from Long Corridor Asset Management LimitedOncoTherapy Science, Inc. announced a private placement to issue 4,000,000 common shares at issue price of ¥19.8 per share for gross proceeds of ¥79,200,000 and 630,000 37th series stock acquisition rights at issue price of ¥9 per stock acquisition right for gross proceeds of ¥5,670,000 on April 10, 2025. The minimum exercise price for the stock acquisition rights is ¥11 and initial exercise price is¥22 yen and the number of potential shares is 63,000,000 shares. The exercise period of stock acquisition rights starts from April 30, 2025 to April 28, 2028. The transaction includes investor participation of Long Corridor Alpha Opportunities Master Fund (LCAO for 3,400,000 shares and 535,500 units and MAP246 Segregated Portfolio (MAP246) for 600,000 shares and 94,500 units. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 28, 2025.공고 • Feb 07OncoTherapy Science, Inc. to Report Q3, 2025 Results on Feb 07, 2025OncoTherapy Science, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)Second quarter 2025 results: JP¥0.91 loss per share (improved from JP¥1.44 loss in 2Q 2024). Revenue: JP¥125.0m (down 40% from 2Q 2024). Net loss: JP¥243.0m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.공고 • Nov 08OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024OncoTherapy Science, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (€62.6m market cap, or US$69.7m).Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)First quarter 2025 results: JP¥1.30 loss per share (improved from JP¥1.99 loss in 1Q 2024). Revenue: JP¥100.0m (down 32% from 1Q 2024). Net loss: JP¥302.0m (loss narrowed 25% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.공고 • Aug 08OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024OncoTherapy Science, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024Reported Earnings • May 13Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)Full year 2024 results: JP¥6.05 loss per share (further deteriorated from JP¥5.80 loss in FY 2023). Revenue: JP¥610.0m (down 46% from FY 2023). Net loss: JP¥1.29b (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.공고 • May 12+ 1 more updateOncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024OncoTherapy Science, Inc. announced that they will report fiscal year 2024 results on May 10, 2024공고 • Apr 05OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investorOncoTherapy Science, Inc. announced a private placement of 540,000 36th stock acquisition rights at a price of ¥7 per warrant for the gross proceeds of ¥3,780,000 on April 5, 2024. The transaction will include participation from new investor, Long Corridor Asset Management Limited, Long Corridor Alpha Opportunities Master Fund. The warrants will be convertible into common shares at an exercise of ¥19 per share. The transaction has been approved by the shareholders of the company and is expected to close on April 22, 2024.Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)Third quarter 2024 results: JP¥1.27 loss per share (improved from JP¥1.56 loss in 3Q 2023). Revenue: JP¥110.0m (down 41% from 3Q 2023). Net loss: JP¥277.0m (loss narrowed 7.7% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.공고 • Feb 10OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024OncoTherapy Science, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€29.0m market cap, or US$31.2m).Reported Earnings • Nov 13Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)Second quarter 2024 results: JP¥1.44 loss per share (improved from JP¥1.74 loss in 2Q 2023). Revenue: JP¥208.0m (up 61% from 2Q 2023). Net loss: JP¥310.0m (loss narrowed 7.7% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.공고 • Nov 10OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023OncoTherapy Science, Inc. announced that they will report Q2, 2024 results on Nov 10, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)First quarter 2024 results: JP¥1.99 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥148.0m (down 62% from 1Q 2023). Net loss: JP¥400.0m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.공고 • Aug 10OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023OncoTherapy Science, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$60.4m).New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€52.0m market cap, or US$56.8m).Reported Earnings • May 17Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)Full year 2023 results: JP¥5.80 loss per share (improved from JP¥13.71 loss in FY 2022). Revenue: JP¥1.13b (down 1.6% from FY 2022). Net loss: JP¥1.12b (loss narrowed 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.공고 • May 12OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023OncoTherapy Science, Inc. announced that they will report fiscal year 2023 results on May 12, 2023Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)Third quarter 2023 results: JP¥1.56 loss per share (improved from JP¥4.73 loss in 3Q 2022). Revenue: JP¥185.0m (up 95% from 3Q 2022). Net loss: JP¥300.0m (loss narrowed 67% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공고 • Feb 09OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023OncoTherapy Science, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023Reported Earnings • Nov 06Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)Second quarter 2023 results: JP¥1.74 loss per share (improved from JP¥3.72 loss in 2Q 2022). Revenue: JP¥129.0m (down 12% from 2Q 2022). Net loss: JP¥336.0m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.공고 • Nov 04OncoTherapy Science, Inc. to Report Q2, 2023 Results on Nov 04, 2022OncoTherapy Science, Inc. announced that they will report Q2, 2023 results on Nov 04, 2022Reported Earnings • Aug 07First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)First quarter 2023 results: JP¥1.44 loss per share (up from JP¥3.00 loss in 1Q 2022). Revenue: JP¥385.0m (up 314% from 1Q 2022). Net loss: JP¥277.0m (loss narrowed 48% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.공고 • Aug 05OncoTherapy Science, Inc. to Report Q1, 2023 Results on Aug 05, 2022OncoTherapy Science, Inc. announced that they will report Q1, 2023 results on Aug 05, 2022Reported Earnings • Jun 24Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.공고 • May 12OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022.Reported Earnings • May 11Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공고 • May 04OncoTherapy Science, Inc. to Report Fiscal Year 2022 Results on May 06, 2022OncoTherapy Science, Inc. announced that they will report fiscal year 2022 results on May 06, 2022Reported Earnings • Feb 06Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥4.73 loss per share (down from JP¥2.42 loss in 3Q 2021). Revenue: JP¥95.0m (up 58% from 3Q 2021). Net loss: JP¥910.0m (loss widened 114% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공고 • Feb 04OncoTherapy Science, Inc. to Report Q3, 2022 Results on Feb 04, 2022OncoTherapy Science, Inc. announced that they will report Q3, 2022 results on Feb 04, 2022Reported Earnings • Nov 06Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥147.0m (up 149% from 2Q 2021). Net loss: JP¥695.0m (loss widened 59% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 08First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: JP¥93.0m (up 127% from 1Q 2021). Net loss: JP¥534.0m (loss widened 68% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 25Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • May 09Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.공고 • Apr 29OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment ArmOn April 28, 2021, OncoTherapy Science, Inc. (TSE:4564) closed the transaction.공고 • Apr 13OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in fundingOncoTherapy Science, Inc. (TSE:4564) announced that it will issue 350,000 31st stock acquisition rights at a price of ¥35 per stock acquisition rights for gross proceeds of ¥12,250,000 on April 12, 2021. Each stock acquisition right is convertible into 100 shares. The stock acquisition right will be convertible into a total of 35,000,000 potential shares of the company. The initial exercise price of the stock acquisition right will be ¥123, minimum exercise price will be ¥74 and has no maximum exercise price. The transaction will take place through third party allotment. The company will pay attorney's fees, stock acquisition rights evaluation costs, and other administrative costs such as securities registration statement, document preparation fee and change registration fee. The stock acquisition rights can be exercised from April 30, 2021 to May 1, 2023. The transaction is expected to close on April 28, 2021. The transaction was approved by the board of directors of the company.Reported Earnings • Feb 08Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥60.0m (up 5.3% from 3Q 2020). Net loss: JP¥426.0m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.공고 • Feb 06OncoTherapy Science, Inc. to Report Q3, 2021 Results on Feb 05, 2021OncoTherapy Science, Inc. announced that they will report Q3, 2021 results on Feb 05, 2021Is New 90 Day High Low • Dec 23New 90-day low: €0.83The company is down 43% from its price of €1.47 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period.Is New 90 Day High Low • Dec 07New 90-day low: €0.96The company is down 3.0% from its price of €0.99 on 08 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period.Reported Earnings • Nov 08Second quarter 2021 earnings released: JP¥2.48 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥59.0m (up 20% from 2Q 2020). Net loss: JP¥438.0m (loss narrowed 28% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Sep 25New 90-day high: €1.47The company is up 4.0% from its price of €1.41 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.공고 • Aug 24OncoTherapy Science, Inc. to Report Q1, 2021 Results on Aug 07, 2020OncoTherapy Science, Inc. announced that they will report Q1, 2021 results on Aug 07, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 30O 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: 30O 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장OncoTherapy Science 배당 수익률 vs 시장30O의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (30O)n/a시장 하위 25% (DE)1.5%시장 상위 25% (DE)4.7%업계 평균 (Biotechs)2.4%분석가 예측 (30O) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 30O 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 30O 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 30O 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: 30O 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/16 05:37종가2026/07/16 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스OncoTherapy Science, Inc.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kiyokazu YamazakiIchiyoshi Research Institute Inc.Toshiyuki IwataMizuho Securities Co., Ltd.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 4 highly experienced directors. 2 independent directors (3 non-independent directors). Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • May 08OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026OncoTherapy Science, Inc., Annual General Meeting, Jun 23, 2026.
공고 • Nov 07OncoTherapy Science, Inc. to Report Q2, 2026 Results on Nov 07, 2025OncoTherapy Science, Inc. announced that they will report Q2, 2026 results on Nov 07, 2025
공고 • Aug 08OncoTherapy Science, Inc. to Report Q1, 2026 Results on Aug 08, 2025OncoTherapy Science, Inc. announced that they will report Q1, 2026 results on Aug 08, 2025
공고 • May 09+ 1 more updateOncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025OncoTherapy Science, Inc., Annual General Meeting, Jun 24, 2025.
공고 • Apr 28OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management LimitedOn April 28, 2025, OncoTherapy Science, Inc., closed the transaction.
공고 • Apr 10OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding from Long Corridor Asset Management LimitedOncoTherapy Science, Inc. announced a private placement to issue 4,000,000 common shares at issue price of ¥19.8 per share for gross proceeds of ¥79,200,000 and 630,000 37th series stock acquisition rights at issue price of ¥9 per stock acquisition right for gross proceeds of ¥5,670,000 on April 10, 2025. The minimum exercise price for the stock acquisition rights is ¥11 and initial exercise price is¥22 yen and the number of potential shares is 63,000,000 shares. The exercise period of stock acquisition rights starts from April 30, 2025 to April 28, 2028. The transaction includes investor participation of Long Corridor Alpha Opportunities Master Fund (LCAO for 3,400,000 shares and 535,500 units and MAP246 Segregated Portfolio (MAP246) for 600,000 shares and 94,500 units. The transaction has been approved by the board of directors of the company. The transaction is expected to close on April 28, 2025.
공고 • Feb 07OncoTherapy Science, Inc. to Report Q3, 2025 Results on Feb 07, 2025OncoTherapy Science, Inc. announced that they will report Q3, 2025 results on Feb 07, 2025
Reported Earnings • Nov 10Second quarter 2025 earnings released: JP¥0.91 loss per share (vs JP¥1.44 loss in 2Q 2024)Second quarter 2025 results: JP¥0.91 loss per share (improved from JP¥1.44 loss in 2Q 2024). Revenue: JP¥125.0m (down 40% from 2Q 2024). Net loss: JP¥243.0m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
공고 • Nov 08OncoTherapy Science, Inc. to Report Q2, 2025 Results on Nov 08, 2024OncoTherapy Science, Inc. announced that they will report Q2, 2025 results on Nov 08, 2024
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (29% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Market cap is less than US$100m (€62.6m market cap, or US$69.7m).
Reported Earnings • Aug 11First quarter 2025 earnings released: JP¥1.30 loss per share (vs JP¥1.99 loss in 1Q 2024)First quarter 2025 results: JP¥1.30 loss per share (improved from JP¥1.99 loss in 1Q 2024). Revenue: JP¥100.0m (down 32% from 1Q 2024). Net loss: JP¥302.0m (loss narrowed 25% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
공고 • Aug 08OncoTherapy Science, Inc. to Report Q1, 2025 Results on Aug 09, 2024OncoTherapy Science, Inc. announced that they will report Q1, 2025 results on Aug 09, 2024
Reported Earnings • May 13Full year 2024 earnings released: JP¥6.05 loss per share (vs JP¥5.80 loss in FY 2023)Full year 2024 results: JP¥6.05 loss per share (further deteriorated from JP¥5.80 loss in FY 2023). Revenue: JP¥610.0m (down 46% from FY 2023). Net loss: JP¥1.29b (loss widened 15% from FY 2023). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
공고 • May 12+ 1 more updateOncoTherapy Science, Inc. to Report Fiscal Year 2024 Results on May 10, 2024OncoTherapy Science, Inc. announced that they will report fiscal year 2024 results on May 10, 2024
공고 • Apr 05OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investorOncoTherapy Science, Inc. announced a private placement of 540,000 36th stock acquisition rights at a price of ¥7 per warrant for the gross proceeds of ¥3,780,000 on April 5, 2024. The transaction will include participation from new investor, Long Corridor Asset Management Limited, Long Corridor Alpha Opportunities Master Fund. The warrants will be convertible into common shares at an exercise of ¥19 per share. The transaction has been approved by the shareholders of the company and is expected to close on April 22, 2024.
Reported Earnings • Feb 11Third quarter 2024 earnings released: JP¥1.27 loss per share (vs JP¥1.56 loss in 3Q 2023)Third quarter 2024 results: JP¥1.27 loss per share (improved from JP¥1.56 loss in 3Q 2023). Revenue: JP¥110.0m (down 41% from 3Q 2023). Net loss: JP¥277.0m (loss narrowed 7.7% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
공고 • Feb 10OncoTherapy Science, Inc. to Report Q3, 2024 Results on Feb 09, 2024OncoTherapy Science, Inc. announced that they will report Q3, 2024 results on Feb 09, 2024
New Risk • Dec 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (€29.0m market cap, or US$31.2m).
Reported Earnings • Nov 13Second quarter 2024 earnings released: JP¥1.44 loss per share (vs JP¥1.74 loss in 2Q 2023)Second quarter 2024 results: JP¥1.44 loss per share (improved from JP¥1.74 loss in 2Q 2023). Revenue: JP¥208.0m (up 61% from 2Q 2023). Net loss: JP¥310.0m (loss narrowed 7.7% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
공고 • Nov 10OncoTherapy Science, Inc. to Report Q2, 2024 Results on Nov 10, 2023OncoTherapy Science, Inc. announced that they will report Q2, 2024 results on Nov 10, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: JP¥1.99 loss per share (vs JP¥1.44 loss in 1Q 2023)First quarter 2024 results: JP¥1.99 loss per share (further deteriorated from JP¥1.44 loss in 1Q 2023). Revenue: JP¥148.0m (down 62% from 1Q 2023). Net loss: JP¥400.0m (loss widened 44% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
공고 • Aug 10OncoTherapy Science, Inc. to Report Q1, 2024 Results on Aug 10, 2023OncoTherapy Science, Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
New Risk • Jun 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risks Shareholders have been diluted in the past year (7.3% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$60.4m).
New Risk • Jun 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥798m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (€52.0m market cap, or US$56.8m).
Reported Earnings • May 17Full year 2023 earnings released: JP¥5.80 loss per share (vs JP¥13.71 loss in FY 2022)Full year 2023 results: JP¥5.80 loss per share (improved from JP¥13.71 loss in FY 2022). Revenue: JP¥1.13b (down 1.6% from FY 2022). Net loss: JP¥1.12b (loss narrowed 56% from FY 2022). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
공고 • May 12OncoTherapy Science, Inc. to Report Fiscal Year 2023 Results on May 12, 2023OncoTherapy Science, Inc. announced that they will report fiscal year 2023 results on May 12, 2023
Board Change • May 10Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent External Director Yoshio Miki was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥1.56 loss per share (vs JP¥4.73 loss in 3Q 2022)Third quarter 2023 results: JP¥1.56 loss per share (improved from JP¥4.73 loss in 3Q 2022). Revenue: JP¥185.0m (up 95% from 3Q 2022). Net loss: JP¥300.0m (loss narrowed 67% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공고 • Feb 09OncoTherapy Science, Inc. to Report Q3, 2023 Results on Feb 10, 2023OncoTherapy Science, Inc. announced that they will report Q3, 2023 results on Feb 10, 2023
Reported Earnings • Nov 06Second quarter 2023 earnings released: JP¥1.74 loss per share (vs JP¥3.72 loss in 2Q 2022)Second quarter 2023 results: JP¥1.74 loss per share (improved from JP¥3.72 loss in 2Q 2022). Revenue: JP¥129.0m (down 12% from 2Q 2022). Net loss: JP¥336.0m (loss narrowed 52% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
공고 • Nov 04OncoTherapy Science, Inc. to Report Q2, 2023 Results on Nov 04, 2022OncoTherapy Science, Inc. announced that they will report Q2, 2023 results on Nov 04, 2022
Reported Earnings • Aug 07First quarter 2023 earnings released: JP¥1.44 loss per share (vs JP¥3.00 loss in 1Q 2022)First quarter 2023 results: JP¥1.44 loss per share (up from JP¥3.00 loss in 1Q 2022). Revenue: JP¥385.0m (up 314% from 1Q 2022). Net loss: JP¥277.0m (loss narrowed 48% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
공고 • Aug 05OncoTherapy Science, Inc. to Report Q1, 2023 Results on Aug 05, 2022OncoTherapy Science, Inc. announced that they will report Q1, 2023 results on Aug 05, 2022
Reported Earnings • Jun 24Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
공고 • May 12OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022OncoTherapy Science, Inc., Annual General Meeting, Jun 21, 2022.
Reported Earnings • May 11Full year 2022 earnings released: JP¥13.71 loss per share (vs JP¥8.85 loss in FY 2021)Full year 2022 results: JP¥13.71 loss per share (down from JP¥8.85 loss in FY 2021). Revenue: JP¥1.15b (up 247% from FY 2021). Net loss: JP¥2.57b (loss widened 65% from FY 2021). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공고 • May 04OncoTherapy Science, Inc. to Report Fiscal Year 2022 Results on May 06, 2022OncoTherapy Science, Inc. announced that they will report fiscal year 2022 results on May 06, 2022
Reported Earnings • Feb 06Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: JP¥4.73 loss per share (down from JP¥2.42 loss in 3Q 2021). Revenue: JP¥95.0m (up 58% from 3Q 2021). Net loss: JP¥910.0m (loss widened 114% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공고 • Feb 04OncoTherapy Science, Inc. to Report Q3, 2022 Results on Feb 04, 2022OncoTherapy Science, Inc. announced that they will report Q3, 2022 results on Feb 04, 2022
Reported Earnings • Nov 06Second quarter 2022 earnings released: JP¥3.72 loss per share (vs JP¥2.48 loss in 2Q 2021)The company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2022 results: Revenue: JP¥147.0m (up 149% from 2Q 2021). Net loss: JP¥695.0m (loss widened 59% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 08First quarter 2022 earnings released: JP¥3.00 loss per share (vs JP¥1.80 loss in 1Q 2021)The company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2022 results: Revenue: JP¥93.0m (up 127% from 1Q 2021). Net loss: JP¥534.0m (loss widened 68% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 25Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • May 09Full year 2021 earnings released: JP¥8.85 loss per share (vs JP¥13.73 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: JP¥332.0m (up 5.1% from FY 2020). Net loss: JP¥1.56b (loss narrowed 30% from FY 2020). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
공고 • Apr 29OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment ArmOn April 28, 2021, OncoTherapy Science, Inc. (TSE:4564) closed the transaction.
공고 • Apr 13OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in fundingOncoTherapy Science, Inc. (TSE:4564) announced that it will issue 350,000 31st stock acquisition rights at a price of ¥35 per stock acquisition rights for gross proceeds of ¥12,250,000 on April 12, 2021. Each stock acquisition right is convertible into 100 shares. The stock acquisition right will be convertible into a total of 35,000,000 potential shares of the company. The initial exercise price of the stock acquisition right will be ¥123, minimum exercise price will be ¥74 and has no maximum exercise price. The transaction will take place through third party allotment. The company will pay attorney's fees, stock acquisition rights evaluation costs, and other administrative costs such as securities registration statement, document preparation fee and change registration fee. The stock acquisition rights can be exercised from April 30, 2021 to May 1, 2023. The transaction is expected to close on April 28, 2021. The transaction was approved by the board of directors of the company.
Reported Earnings • Feb 08Third quarter 2021 earnings released: JP¥2.42 loss per share (vs JP¥3.17 loss in 3Q 2020)The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥60.0m (up 5.3% from 3Q 2020). Net loss: JP¥426.0m (loss narrowed 18% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
공고 • Feb 06OncoTherapy Science, Inc. to Report Q3, 2021 Results on Feb 05, 2021OncoTherapy Science, Inc. announced that they will report Q3, 2021 results on Feb 05, 2021
Is New 90 Day High Low • Dec 23New 90-day low: €0.83The company is down 43% from its price of €1.47 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Dec 07New 90-day low: €0.96The company is down 3.0% from its price of €0.99 on 08 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period.
Reported Earnings • Nov 08Second quarter 2021 earnings released: JP¥2.48 loss per shareThe company reported a solid second quarter result with reduced losses and improved revenues and control over expenses. Second quarter 2021 results: Revenue: JP¥59.0m (up 20% from 2Q 2020). Net loss: JP¥438.0m (loss narrowed 28% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Sep 25New 90-day high: €1.47The company is up 4.0% from its price of €1.41 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
공고 • Aug 24OncoTherapy Science, Inc. to Report Q1, 2021 Results on Aug 07, 2020OncoTherapy Science, Inc. announced that they will report Q1, 2021 results on Aug 07, 2020